We examined the design of the versatile novel self-emulsifying drug delivery systems (SEDDS) type O W W microemulsion formulation which enhances the oral bioavailability by raising the solubility of poorly water soluble compounds. Namely, seven kinds of poorly water soluble compounds such as disopyramide, ibuprofen, ketoprofen, tolbutamide, and other new compounds, as the model compounds were used to compare the plasma concentration proˆle of the compound following single oral administration of each compound to rats and beagle dogs as a solution, an oily solution, a suspension (or a powder), an O W W microemulsion, and a SEDDS type O W W microemulsion. And the enhancing eŠect of the SEDDS type O W W microemulsion on the gastrointestinal absorption of these compounds was evaluated. In the components of the SEDDS type O W W microemulsion, medium chain fatty acid triglyceride (MCT), diglyceryl monooleate (DGMO-C), polyoxyethylene hydrogenated castor oil 40 (HCO-40), and ethanol were used as an oil, a lipophilic surfactant, a hydrophilic surfactant, and a solubilizer, at the mixture ratio of 25 W 5 W 45 W 25 (w W wz), respectively. Thereby, to six kinds of the model compounds except disopyramide, the solubility was from 340 to 98,000 times that in water, and the AUCs in plasma concentration of the compound were equivalent to that of solution or O W W microemulsion administration, or was increased by 1.5 to 78 times that of suspension administration. Accordingly, this novel SEDDS type O W W microemulsion is the versatile, useful formulation which enhances the oral bioavailability by raising the solubility of poorly water soluble compounds.
Introduction
When the compounds are orally administered, the dissolution rate and the stability in a gastrointestinal tract, the permeability and the metabolic activity in a gastrointestinal membrane are considered as the variable factors to the rate and the quantity in the absorption process from a gastrointestine. In poorly water soluble compounds, especially, the dissolution process is mentioned as the factor which greatly in-‰uences the gastrointestinal absorption. The dissolution rate of poorly water soluble compounds is greatly in-‰uenced by the diet and the ‰ow of the bile secretion because of the low solubility or the dissolution rate to water, so the oral bioavailability is low and its variation becomes large. Therefore, even if it has powerful pharmacological activity, the clinical e‹cacy which is expected is sometimes not realized. In order to increase the clinical e‹cacy of the lipophilic compounds following oral administration, many trials which improve the gastrointestinal absorption and raise bioavailability have been made. As the technologies for improvement, for example, there are the compound independent system, pulverization, 1) and the compound W formulation addition system, solid dispersion. 2) These technologies often produce the aggregation of the compound 3) and it is di‹cult for these technologies to maintain the physicochemical stability of the compound, 4) so we focused our attention on the O W W microemulsion. This formulation is the mixture of an oil, surfactants (lipophilic and hydrophilic agent) and an aqueous phase, and if needed, a solubilizer is added and it is oil in water type dispersion system which is thermodynamically stabilized by the interface phase of the surfactants. The O W W microemulsion is expected to increase the solubility by dissolving poorly water soluble compounds into the oil phase and to enhance oral bioavailability. Enhancement of the gastrointestinal absorption by the O W W microemulsion is actually demonstrated with various lipophilic drugs, such as a potent immunosuppressive drug, cyclosporin A 5, 6) and an anti-malaria drug, halofantrine. 7, 8) In the previous studies, we designed the novel O W W microemulsion formulation which enhances the oral bioavailability by raising the solubility of poorly water soluble compounds. 9) But the outer phase of the O W W microemulsion is an aqueous phase, so, if the stability of the microemulsion is taken into consideration, on the occasion of clinical application, development of the SEDDS type O W W microemulsion which does not contain an aqueous phase is desired. This system is the formulation which carries out self-emulsiˆcation under gentle agitation following contact with the aqueous phase within a stomach or an upper small intestine and forms a thermodynamically stable O W W microemulsion with the particle diameter of 100 nm or less. [10] [11] [12] [13] [14] Research is actively performed about poorly water soluble drugs, cyclosporin A 15) and the cholesterol-lowering agent, simvastatin, 16) etc., and for cyclosporin A, as the formulation which enabled the stable gastrointestinal absorption, the SEDDS type O W W microemulsion was put on the market by brand name called Neoral.
Therefore, in this research, we tried to design the versatile novel SEDDS type O W W microemulsion formulation, based on the new O W W microemulsion formulation, which enhanced the oral bioavailability by raising the solubility of poorly water soluble compounds. 9) 
Materials and Methods
Materials: As the examined compounds, AG-041R, BO-653 and ER-1258 were synthesized by Chugai Pharmaceutical Co., Ltd. (Tokyo, Japan). Chloramphenicol, disopyramide, ibuprofen, ketoprofen, tamoxifen and tolbutamide were purchased from Sigma Chemicals Company (MO, USA). Testosterone was purchased from Tokyo Kasei Kogyo Co., Ltd. (Tokyo, Japan).
As the internal standard compounds, AG-090 and ER-1236 were synthesized by Chugai Pharmaceutical Co., Ltd. (Tokyo, Japan).
As reagents, EOO, soybean oil, DGMO-C and HCO-40 were obtained from NIKKO Chemicals Co., Ltd. (Tokyo, Japan). MCT was obtained from NOF Corp. (Tokyo, Japan). Gum arabic was purchased from Sigma Chemicals Company (MO, USA). PEG200, anhydrous ethanol and ethanol were purchased from Wako Pure Chemical industries Ltd. (Osaka, Japan). Sodium carboxymethyl cellulose was purchased from Junsei Chemical Co., Ltd. (Tokyo, Japan). Crystal cellulose (Avicel PH-101) was purchased from Asahi Kasei Corp. (Osaka, Japan). Heparin sodium was purchased from Aventis Pharma Ltd. (Tokyo, Japan). Saline was purchased from Otsuka Pharmaceutical Factory Inc. (Tokushima, Japan). Dulbecco's PBS tablet was purchased from Takara Bio Inc. (Shiga, Japan). PIC-A was purchased from Waters Corp. (MA, USA). Gelatin capsule were purchased from Shionogi Qualicaps Co., Ltd. (Nara, Japan). Formulation examination of model compound entrapped SEDDS type O W W microemulsions: 25 w W wz of an oil (MCT or EOO), 5 or 25 w W wz of a lipophilic surfactant (DGMO-C), 45 or 25 w W wz of a hydrophilic surfactant (HCO-40) warmed and dissolved at 509 C, and 25 w W wz of the anhydrous ethanol solution containing each compound (chloramphenicol, disopyramide, ibuprofen, ketoprofen, tamoxifen, testosterone, tolbutamide, AG-041R, BO-653) was accurately weighed in glass vials. The components were mixed by agitating at room temperature for 10 minutes, model compound entrapped SEDDS type O W W microemulsions were prepared, and the emulsiˆcation rate, the particle diameter, and the compound concentration were measured.
Gastrointestinal Absorption Examination of Model Compound Entrapped Formulations in Rats and Beagle Dogs
Animals: Male rats of Sprague Dawley (SD) strain (7 week-old) were purchased from SLC Japan Inc. (Shizuoka, Japan) and used for experiments at age 8 weeks after breeding for 1 week. On the other hand, eight male beagle dogs (12 month-old) were obtained from Chugai Research Institute for Medical Science Inc. (Shizuoka, Japan). Animals were fasted overnight prior to administration, but freely ingested drinking water. The in vivo study in dogs was a crossover design and each administration was separated by 1 week. All animal experiments complied with the standards set out in the guidelines of Chugai Pharmaceutical Co., Ltd.
Preparation of compound entrapped formulations:
Each of the compound entrapped formulations for administration, a solution, an oily solution, a suspension, a powder, an O W W microemulsion, and a SEDDS type O W W microemulsion were prepared for disopyramide, ibuprofen, ketoprofen, tolbutamide, AG-041R, BO-653 and ER-1258.
Solution: After ethanol was added to each compound except B0-653 and dissolved in it, 4 volumes of 66.7 (w W w) z PEG200 solution were added to 1 volume of the ethanol solution containing each compound and mixed. As the solution for rats, 1 mg W mL of ER-1258 solution and 10 mg W 3 mL of other compound solutions were prepared. Also, as the solution for beagle dogs, 3 mgW mL of ER-1258 solution and 10 mg W mL of AG-041R solution were prepared.
Oily solution: As the oily solution for rats, soybean oil was added to BO-653 and mixed, and 50 mg W 3 mL of BO-653 oily solution was prepared. For ER-1258, MCT was added to ER-1258 and dissolved, and 1 mgW mL of ER-1258 oily solution was prepared.
Suspension: Each compound except BO-653 was ground andˆltered by mesh of 45 to 75 mm. In an agate mortar, 5z gum arabic solution was added little by little to ER-1258. 0.5z CMC-Na solution was also added to the other compounds by the same method. It was mixed until it became uniform and as the suspensions for rats, 1 mg W mL of ER-1258 and 10 mg W 3 mL of the other compound suspensions and as the suspension for beagle dogs, 3 mg W mL of ER-1258 suspension were prepared. Moreover, for BO-653, after 0.5z CMC-Na solution was added to BO-653, it was mixed until it became uniform using a polytron homogenizer and 50 mg W 3 mL of BO-653 suspension was prepared.
O W W microemulsion: 5 wW wz of an oil (MCT), 1 wW wz of a lipophilic surfactant (DGMO-C), 9 w W wz of a hydrophilic surfactant (HCO-40) warmed and dissolved at 509 C, and 5 w W wz of the anhydrous ethanol containing each compound (1000 mg W 3 mL of BO-653 and 200 mg W 3 mL of others except ER-1258 for rats, and 200 mg W mL of AG-041R for beagle dogs) were accurately weighed in glass vials. The components were mixed by agitating at room temperature for 10 minutes. Then, 80 w W wz of PBS (pH 6.8) was added to this mixture, it was agitated at room temperature for 2 hours, and 50 mg W 3 mL of BO-653, 10 Powder in capsule: As the powder in capsule for beagle dogs, AG-041R was ground andˆltered by mesh of 45 to 75 mm. After AG-041R and equivalent crystal cellulose were put into a mortar, and mixed, the gelatin capsule of No. 2 wasˆlled up with this powder.
Administration: As for the rats, after anesthesia with diethylether during surgery, the femoral artery was cannulated with the polyethylene tube-50ˆlled with 50 IU W mL of sodium heparin in saline. After rats werê xed in the experimental cage for blood collection and recovered from anesthesia after an interval of 2 hours, the single administration of each compound into the stomach was carried out using oral sonde as a solution, an oily solution, a suspension, and an O W W microemulsion at a dose of 10 mg W 3 mL W kg (3 mg W 3 mL W kg for ER-1258 and 50 mg W 3 mL W kg for BO-653). As for the SEDDS type O W W microemulsion, after the single administration of each compound into the stomach was carried out using oral sonde at a dose of 10 mg W 0.6 mL W kg (3 mg W 0.6 mL W kg for ER-1258 and 50 mg W 0.6 mL W kg for BO-653), PBS (pH 6.8) at a volume of 2.4 mL W kg was continuously administered by a similar method.
On the other hand, for beagle dogs, after the beagle dogs wereˆxed, the single administration of ER-1258 and AG-041R as a solution, a suspension and an O W W microemulsion (AG-041R only) at a dose of 3 mg W mL W kg for ER-1258 and 10 mg W mL W kg for AG-041R was carried out using the disposable syringe of 30 mL through the Saˆd Nelaton catheter of 40 cm inserted into the stomach from mouth. For the powder and the SEDDS type O W W microemulsion, after these formulations wereˆlled up into the gelatin capsules, the compulsory single administration of each compound at a dose of 30 mg W dog for ER-1258 and 100 mg W dog for AG-041R was orally carried out. In addition, the drinking water of 30 mL was continuously administered after administration of each formulation.
The volume in the case of administration was set up so that it may become the designed dose by correcting in terms of the measurement of each concentration of the compounds in the formulation.
Sample collection: For the rats, blood samples of 0.3 mL were withdrawn into non-heparinized tubes through the polyethylene tube-50ˆlled with sodium heparin in saline, inserted into the femoral artery at designated time intervals (before administration and 5, 15, 30 minutes, 1, 2, 4, 6, 8, 24 hours after administration). The collected blood samples were centrifuged at 49 C, 15000 rpm for 3 minutes, and the plasma samples were taken and transferred into cap tubes. Plamsa samples were frozen and stored at -809 C until measurement.
On the other hand, for beagle dogs, blood samples of 2 mL were collected from a peripheral vein into the heparin-coated sampling tube using the disposable syringe of 2.5 mL with a 23 gauge needle at designated time intervals (before administration and 5, 15, 30 minutes, 1, 2, 4, 6, 8, 24 hours after administration). The collected blood samples were centrifuged at 49 C, 3000 rpm for 15 minutes, and the plasma samples were taken and transferred into cap tubes. Plamsa samples were frozen and stored at -809 C until measurement.
The evaluation of physical properties of the compound entrapped SEDDS type O W W microemulsions: 2.4 mL of PBS (pH 6.8) was added to 600 mg of the compound entrapped SEDDS type O W W microemulsions and they were agitated at the rate of 130 to 150 rpm at room temperature, and the dispersibility (emul-siˆcation rate) was measured.
Thereafter, these mixtures were agitated at high speed, room temperature for 2 hours and were perfectly emulsiˆed. The appearance was observed and they were diluted with PBS (pH 6.8) moderately and the particle diameters were measured using a dynamic light scattering particle sizer (NICOMP370).
The measurement of the content of model compounds in formulation: Ethanol was added to each compound entrapped SEDDS type O W W microemulsions for formulation examination and each formulation for in vivo study, and all formulations were mixed and dissolved. For tne O W W microemulsions, the compound in the inner (oil) phase and that in the outer (aqueous) phase were dissolved together in ethanol. After diluting using the mobile phase of HPLC, the concentrations of each compound were measured by the absolute standard curve method using HPLC. HPLC conditions are shown in Table 1 
The Measurement of the Concentration of Each Compound in Plasma
ER-1258 and AG-041R: After the organic solvent containing the internal standard (ER-1236 and AG-090 for ER-1258 and AG-041R, respectively) was added and mixed with the standard plasma containing the various concentrations of each compound or the sample plas- ma, centrifugation was carried out at 49 C, 15000 rpm for 5 minutes. After the layer of the organic solvent was removed as completely as possible and transferred into glass tubes, this was evaporated with nitrogen gas at 409 C. The samples were reconstituted with the mobile phase of LC. The centrifugation was carried out at 49 C, 15000 rpm for 5 minutes and the concentrations of each compound in the supernatant were measured by LC W MS or HPLC under the conditions shown in Table 1-2. BO-653, disopyramide, ibuprofen, ketoprofen and tolbutamide: After an organic solvent was added to the standard plasma containing the various concentrations of each compound or the sample plasma, the mixture was shaken at room temperature for 10 minutes. After centrifugation was carried out at 49 C, 3000 rpm for 5 minutes, the layer of the organic solvent was removed as completely as possible and transferred into glass tubes. This was evaporated with nitrogen gas at 409 C and reconstituted with the mobile phase of HPLC. The concentrations of each compound in this solution were measured by HPLC under the conditions shown in Table 1 The pharmacokinetic parameters of in vivo studies were expressed as the mean±S.D. of four orˆve animals. The diŠerences for each parameter to the time of suspension (or powder) administration were assessed using the multiple comparison analysis by the Tukey method. Pº0.05 was deˆned as statistically signiˆcant.
Results
The physicochemical properties of model compound entrapped SEDDS type O W W microemulsions for formulation examination: The dispersibility (emulsiˆcation rate), the particle diameter and the compound solubility at the time of making the O W W microemulsions from the model compound entrapped SEDDS type O W W microemulsions, which were prepared by changing the mixture ratio of the lipophilic and hydrophilic surfactants, are shown in Table 2 -1 and 2-2.
When MCT and EOO were used as oils, the formulations were more promptly emulsiˆed in the mixture ratio of DGMO-C:HCO-40＝1:9, compared with DGMO-C:HCO-40＝5:5, and the O W W microemulsion, which was more clear and the particle diameter was small, was formed by this mixture ratio of 1:9. Moreover, the MCT entrapped O W W microemulsion was excellent in these properties compared with the EOO entrapped O W W microemulsion.
On the other hand, concerning the solubility of the model compounds, that of chloramphenicol and disopyramide only increased 8 and 50 times that in water, respectively, because of the comparatively good dissolution in water, but for ibuprofen, ketoprofen, tamoxifen, testosterone, tolbutamide, AG-041R and BO-653, the solubility that was from 340 to 98,000 times that in water was obtained. Fig. 1 and Table 4 -A, respectively. Moreover, the ER-1258 concentrations for each formulation are shown in Table 3 .
The solubility of ER-1258 was below 1 mg W mL in the 1st solution (pH 1.2) and the 2nd solution (pH 6.8) of a Japanese pharmacopoeia disintegration test, but by entrapping this compound in the SEDDS type O W W microemulsion, the solubility reached 6,000 times or more that in water, about 6 mg W mL.
On the other hand, the ratios of Cmax and AUC following oral administration as a solution, a MCT solution, a SEDDS type O W W microemulsion to those of suspension administration were 1.5, 0.76, 2.6 and 1.4, 0.82, 1.8, respectively. A signiˆcant increase of Cmax and AUC was obtained only in the administration of the SEDDS type O W W microemulsion (it was Pº0.01 for Cmax and Pº0.05 for AUC).
Other compounds in rats: The plasma concentra- Fig. 2-A, B, 3-A, B , C, D and Table 4 -B, C, 5-A, B, C, D, respectively. For AG-041R, the AUC ratios following oral administration as a solution, an O W W microemulsion, and a SEDDS type O W W microemulsion to that of suspension administration were 1.2, 2.8 and 2.1, respectively. A signiˆcant increase of AUC was obtained only in the administration of the SEDDS type O W W microemulsion (Pº0.05). In addition, Cmax increased sig-niˆcantly also in all formulations (from Pº0.05 to Pº0.001).
For BO-653, the AUC ratios following oral administration as an oily solution, an O W W microemulsion, and a SEDDS type O W W microemulsion to that of suspension administration were 110, 64 and 78, respectively. 
microemulsion (Pº0.05). A signiˆcant diŠerence was not demonstrated in Cmax.
ER-1258 in beagle dogs: The plasma concentration proˆle and pharmacokinetic parameters of ER-1258 following single oral administration of ER-1258 to fasted beagle dogs as a solution, a suspension and a SEDDS type O W W microemulsion at a dose of 3 mg W kg are shown in Fig. 4-A and Table 6 -A, respectively. Moreover, the ER-1258 concentrations of each formula-tion are shown in Table 3 .
The solubility of ER-1258 reached 80,000 times or more that in water (below 1 mg W mL), about 80 mg W mL by entrapping this compound in the SEDDS type O W W microemulsion.
On the other hand, the ratios of Cmax and AUC following oral administration as a solution, a SEDDS O W W microemulsion to those of suspension administration were 2.3, 4.7 and 1.9, 3.9, respectively. A sig- AG-041R in beagle dogs: The plasma concentration proˆle and pharmacokinetic parameters of AG-041R following single oral administration of AG-041R to fasted beagle dogs as a solution, a powder, an O W W microemulsion, and a SEDDS type O W W microemulsion at a dose of 10 mg W kg are shown in Fig. 4-B and Table 6 -B, respectively.
The AUC ratios following oral administration as a solution, an O W W microemulsion and a SEDDS O W W microemulsion to that of powder administration were 6.7, 8.9 and 11.3, respectively. A signiˆcant increase of AUC was demonstrated in all formulations (Pº0.05).
Cmax signiˆcantly increased only in the administration of the SEDDS type O W W microemulsion (Pº0.05).
Discussion
The purpose of this research is to verify whether the SEDDS type O W W microemulsion can enhance the gastrointestinal absorption based on improving the solubility of poorly water soluble compounds on parity with the novel O W W microemulsion which we designed previously. 9) The SEDDS type O W W microemulsion is an isotropic mixture of an oil, surfactants (lipophilic and hydrophilic agent) and if needed, a solubilizer is added. It is known that the mixtures of these materials with an aqueous phase become a clear isotropic region, a gel, a rough emulsion, a W W O microemulsion, and an O W W microemulsion by the mixture ratio and the width Table 4 ). Although ER-1258 is a weak acid compound with a molecular weight of 700 and a clog P of 9.3, and the solubility is also below 1 mg W mL in theˆrst solution (pH 1.2) and the second solution (pH 6.8) of a Japanese pharmacopoeia disintegration test, by making it the SEDDS type O W W microemulsion showed the solubility of 80,000 times or more that in water, so it was shown that the gastrointestinal absorption can be increased by this improvement of solubility. In addition, the in‰uence of the bile secreted into a small intestinal tract was considered as a reason to which the gastrointestinal absorption was not able to be increased as the degree of improvement of the solubility by the SEDDS type O W W microemulsion. That is, the bile is continuously secreted into a small intestinal tract in rats and helps to dissolve the compounds administered as a suspension. Therefore, it was thought that the ratio of the solubility in the SEDDS type O W W microemulsion to water is smaller in the intestinal tract than in vitro, and the enhancing eŠect of gastrointestinal absorption was not able to be increased in line with the degree of improvement of the solubility. Moreover, we suppose that this phenomenon applies to not only ER-1258, but the many other poorly water soluble compounds.
Moreover, the comparison examination of the concentration proˆle of compound in plasma following single oral administration to rats as a suspension, a solution, an O W W microemulsion and a SEDDS type O W W microemulsion was also carried out using six kinds of compounds (AG-041R, BO-653, disopyramide, ibuprofen, ketoprofen, tolbutamide) as the model compounds. AG-041R is a neutral compound with a molecular weight of 550 and a clog P of 4.3, and BO-653 is a neutral compound with a molecular weight of 390 and a clog P of 10.5. When the compounds were administered as an O W W microemulsion and a SEDDS type O W W microemulsion, the AUC ratios to the time of suspension administration were within the limits of 1.6 to 64 and 1.5 to 78, respectively, and the signiˆcant increase of AUC was demonstrated. ( Table 4 and 5) Moreover, it was shown that the SEDDS type O W W microemulsion had the AUC of the same degree as that of the O W W microemulsion, therefore, it was veriˆed that the SEDDS type O W W microemulsion which consists of oil and surfactants was a very useful formulation which became the good O W W microemulsion in the gastrointestinal tract and the gastrointestinal absorption of poorly water soluble compounds could be improved. In addition, the signiˆcant diŠerence was not observed in disopyramide by the AUC ratio to the time of suspension administration. As to the reason for this, we supposed that disopyramide did not stay only in the oil phase but it also existed in the aqueous phase because of the comparatively good solubility in water, so the enhancement eŠect of the O W W microemulsion was not demonstrated.
There is the high possibility that the drug entrapped SEDDS type O W W microemulsion will be administered to human as a capsule form clinically. Then, using the beagle dogs which can be administered a capsule form, AG-041R and ER-1258 as the model compounds, like the rat, the encapsuled SEDDS type O W W microemulsion was evaluated to be able to improve the gastrointestinal absorption on a parity with the O W W microemulsion. When these compounds were administered as an O W W microemulsion (AG-041R only) and a SEDDS type O W W microemulsion, the AUC ratios to the time of suspension administration were 8.9 and 3.9 to 11.3, respectively ( Table 6) , and it was shown that the AUC for the SEDDS type O W W microemulsion was the same or more than that of the O W W microemulsion. As there was a report 16) which showed the improving eŠect in bioavailability of simvastatin by the SEDDS type O W W microemulsion in the beagle dog, we were also able to verify in the beagle dog like the rat that the SEDDS type O W W microemulsion which consists of oil and surfactants transformed into the good O W W microemul-sion in the gastrointestinal tract, and could improve the gastrointestinal absorption of poorly water soluble compounds. This event showed that it is possible to enclose the SEDDS type O W W microemulsion in a capsule form and administer it to human. Moreover, since it is thought that in this new formulation of the SEDDS type O W W microemulsion, the entrapped compounds also have the advantage which is not in-‰uenced by the dissolution process of the compounds in the gastrointestinal tract, this formulation is expected also as that which is able to mitigate the in‰uence of the diets and the ‰ow of the bile secretion and decrease the variation in bioavailability.
Conclusion
In the components of the SEDDS type O W W microemulsion, medium chain fatty acid triglyceride (MCT), diglyceryl monooleate (DGMO-C), polyoxyethylene hydrogenated castor oil 40 (HCO-40) and ethanol were used as an oil, a lipophilic surfactant, a hydrophilic a surfactant and a solubilizer, respectively, and it was considered as the mixture ratio of 25 W 5 W 45 W 25 (w W wz). Thereby, to six kinds of poorly water soluble compounds such as ibuprofen, ketoprofen, tolbutamide, AG-041R, BO-653, and ER-1258, solubility that was from 340 to 98,000 times that in water was obtained, and the AUCs in plasma concentration of the compounds in rats and beagle dogs were equivalent to that of solution or O W W microemulsion administration or increased by 1.5 to 78 times that of suspension administration, so an enhancing eŠect of the gastrointestinal absorption, based on improving its solubility, was demonstrated. Accordingly, this novel SEDDS type O W W microemulsion is the versatile, useful formulation which enhances the oral bioavailability by raising the solubility of poorly water soluble compounds.
